[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100631525":3},{"organization":4,"armGroups":7,"interventions":14,"overallOfficials":20,"centralContacts":21,"locations":20,"responsibleParty":27,"collaborators":20,"id":29,"slug":30,"hasResults":31,"nctId":32,"briefTitle":33,"officialTitle":34,"acronym":20,"eligibilityCriteria":35,"healthyVolunteers":31,"sex":36,"minAge":37,"maxAge":20,"enrollmentInfo":38,"targetDuration":20,"studyType":41,"phases":42,"briefSummary":44,"conditions":45,"keywords":20,"overallStatus":47,"whyStopped":20,"lastUpdateSubmitDate":48,"lastUpdatePostDateStruct":49,"startDateStruct":52,"completionDateStruct":54,"leadSponsor":56,"locationsCount":20},{"fullName":5,"class":6},"SymKardia","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":12},"Therapy","EXPERIMENTAL","Central sympathetic nerve ablation therapy",[13],"Device: Central sympathetic nerve ablation",[15],{"type":16,"name":17,"description":18,"armGroupLabels":19,"otherNames":20},"DEVICE","Central sympathetic nerve ablation","Catheter-based ablation of an extra-cardiac nerve target",[9],null,[22],{"name":23,"role":24,"phone":25,"phoneExt":20,"email":26},"Imad Libbus, PhD","CONTACT","651-242-4431","imad.libbus@symkardia.com",{"type":28,"investigatorFullName":20,"investigatorTitle":20,"investigatorAffiliation":20,"oldNameTitle":20,"oldOrganization":20},"SPONSOR","100631525","sympathetic-ablation-for-ventricular-arrhythmias-100631525",false,"NCT07501819","Sympathetic Ablation for Ventricular Arrhythmias","Early Feasibility Study of Central Sympathetic Nerve Ablation for Treatment of Ventricular Arrhythmias","Inclusion Criteria:\n\n1. Age 18 or older at the time of informed consent\n2. Willing and capable of providing written informed consent\n3. Implanted ICD or CRT-D\n4. Recurrent VT leading to ICD therapy (ATP or shock)\n5. Indicated for catheter ablation of VT per international guidelines\n6. No prior instrumentation or resection of the stellate ganglia, or surgical procedure that may have disturbed the stellate ganglia\n\nExclusion Criteria:\n\n1. Contraindication to percutaneous femoral arterial access\n2. Heparin-induced thrombotic thrombocytopenia\n3. Prior surgical sympathectomy\n4. ECMO therapy in the past 30 days\n5. Contraindicated for advanced heart failure therapies (LVAD or heart transplantation)\n6. A most recently documented LVEF \\\u003C20% in the past 30 days\n7. Receiving inotropic drug therapy\n8. Women of childbearing potential who are pregnant or breastfeeding. Women of childbearing potential must have a negative pregnancy test at enrollment\n9. A life expectancy of less than 12 months according to physician judgment\n10. Involvement in any concurrent clinical study with an investigational therapy","ALL","18 Years",{"count":39,"type":40},10,"ESTIMATED","INTERVENTIONAL",[43],"NA","Enrolled patients will undergo an acute procedure in which a catheter is inserted near the heart to ablate a sympathetic nerve, reducing signals that trigger ventricular arrhythmias.",[46],"Ventricular Tachycardia (VT)","NOT_YET_RECRUITING","2026-03-24",{"date":50,"type":51},"2026-03-30","ACTUAL",{"date":53,"type":40},"2026-04",{"date":55,"type":40},"2027-09",{"name":5,"class":6}]